There are a vast range of industrial processes used to manufacture the chemicals we need, many of which have high energy requirements, complex multi-step reactions, and toxic by-products. Chemical manufacturing is an $11tn market and there is a strong demand for more sustainable, climate-friendly, efficient approaches. One available solution is to use proteins that catalyse chemical transformations (enzymes), thereby cutting out intermediate reaction steps and harmful by-products, and dramatically improving process efficiencies.
Imperagen is building a novel platform that combines cutting-edge computational simulation with automated, high-throughput molecular biology to accelerate the design, optimisation, and validation of new industrial enzymes.
Imperagen was founded by Dr Andrew Almond, Dr Andrew Currin, and Dr Timothy Eyes in 2022 to commercialise their research at the University of Manchester’s Institute of Biotechnology.